ASP Isotopes (NASDAQ:ASPI - Get Free Report) was downgraded by Wall Street Zen from a "sell" rating to a "strong sell" rating in a report issued on Saturday, Wall Street Zen reports.
Separately, Weiss Ratings reissued a "sell (d-)" rating on shares of ASP Isotopes in a report on Monday, September 21st. Two investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Hold" and a consensus target price of $12.00.
View Our Latest Stock Analysis on ASPI
ASP Isotopes Trading Down 3.1%
ASP Isotopes stock opened at $1.10 on Friday. The company has a quick ratio of 3.85, a current ratio of 3.87 and a debt-to-equity ratio of 0.76. ASP Isotopes has a 52 week low of $1.03 and a 52 week high of $8.60. The stock has a 50-day moving average price of $2.32 and a 200 day moving average price of $4.45.
Insiders Place Their Bets
In related news, COO Robert Ainscow sold 67,500 shares of the company's stock in a transaction dated Monday, November 16th. The stock was sold at an average price of $1.57, for a total value of $105,975.00. Following the completion of the transaction, the chief operating officer owned 2,158,441 shares of the company's stock, valued at approximately $3,388,752.37. This represents a 3.03% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director John Ryan purchased 15,000 shares of the stock in a transaction on Wednesday, September 30th. The shares were acquired at an average price of $2.68 per share, for a total transaction of $40,200.00. Following the transaction, the director directly owned 675,222 shares of the company's stock, valued at $1,809,594.96. This represents a 2.27% increase in their position. The SEC filing for this purchase provides additional information. Insiders have sold 312,785 shares of company stock worth $1,005,862 in the last 90 days. 14.40% of the stock is currently owned by company insiders.
Institutional Investors Weigh In On ASP Isotopes
Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. BlackRock Inc. acquired a new stake in ASP Isotopes during the second quarter worth $57,331,000. Encompass Capital Advisors LLC acquired a new position in shares of ASP Isotopes in the 1st quarter valued at $30,551,000. Alyeska Investment Group L.P. lifted its stake in shares of ASP Isotopes by 5.6% in the 2nd quarter. Alyeska Investment Group L.P. now owns 2,843,503 shares of the company's stock valued at $17,687,000 after purchasing an additional 151,337 shares during the last quarter. AWM Investment Company Inc. purchased a new position in shares of ASP Isotopes during the 2nd quarter worth $9,837,000. Finally, Philadelphia Financial Management of San Francisco LLC purchased a new position in shares of ASP Isotopes during the 2nd quarter worth $8,353,504. Hedge funds and other institutional investors own 16.80% of the company's stock.
ASP Isotopes Company Profile
(
Get Free Report)
ASP Isotopes Inc. is an advanced materials company focused on producing and commercializing enriched isotopes. Its proprietary Aerodynamic Separation Process is designed to separate isotopes and support production across a range of applications. The company's targeted products include isotopes used in medical imaging and pharmaceuticals, semiconductor manufacturing, quantum technologies and nuclear energy. Examples include molybdenum-100, silicon-28 and ytterbium-176. ASP Isotopes is headquartered in the United States and has pursued isotope-enrichment operations in South Africa.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider ASP Isotopes, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ASP Isotopes wasn't on the list.
While ASP Isotopes currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.